提高慢性乙型肝炎功能性治愈率的新方法和新策略

New methods and strategies to improve functional cure rate of chronic hepatitis B

慢性乙型肝炎（CHB）是由乙型肝炎病毒（HBV）引起的以肝脏反复炎性病变为主要特征的疾病，可进一步发展为失代偿期肝硬化、肝癌或肝衰竭。目前CHB的抗病毒治疗药物主要是核苷（酸）类似物和干扰素两大类，虽能有效抑制病毒复制，但由于不能破坏共价闭合环状DNA（cccDNA），仍面临HBsAg清除率低、停药后易复发等问题，难以实现功能性治愈（或临床治愈）。新型药物及生物制剂的兴起为CHB实现功能性治愈提供新的思路和方向。本文就CHB功能性治愈的新方法及方案作一阐述。

Chronic hepatitis B （CHB）, characterized by recurrent liver inflammation caused by hepatitis B virus （ HBV ） , can further develop into decompensated liver cirrhosis,liver cancer or liver failure. The currently used therapeutic drugs nueleos （ t ） ide analogues and interferon can effectively inhibit virus replication, but it is difficult to achieve functional cure （ clinical cure ） because of their inability to destroy covalently closed ring DNA （cceDNA）. So we are still facing problems of low HBsAg clearance rate and high recurrence rate after drug withdraw. In recent years, the emerging of new drugs and biological agents provide novel ideas and directions for the functional cure of CHB. This article briefly reviews the new therapeutic methods and strategies for functional cure of CHB.